These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The effect of seventy-two-hour continuous infusion of long-acting natriuretic peptide on acute ischemic renal failure in the rat.
    Author: Alhumoud HM.
    Journal: Ren Fail; 2006; 28(7):577-81. PubMed ID: 17050241.
    Abstract:
    OBJECTIVES: Atrial natriuretic peptide (ANP(1-28)) protects the kidneys against acute renal failure in animals; however, its use in humans has been disappointing. Long-acting natriuretic peptide (LANP(1-30)) has natriuretic and diuretic actions similar to ANP(1-28), but it has a longer half-life and a different receptor site. Therefore, this study's aim was to determine if LANP(1-30) has better renal protection than ANP(1-28), which may make it useful in the treatment of acute renal failure. SUBJECTS/METHODS: Three groups of male Sprague-Dawley rats were used, each with a body weight between 250-300 gm. Group 1 (ischemia only, n = 6) had a right nephrectomy followed by 30 minutes of left renal pedicle clamping. Group 2 (LANP Peptide treated, n = 7) had renal ischemia similar to Group 1, followed by an intraperitoneal bolus of 10 microg of LANP(1-30) and the placement of mini-osmotic pumps delivering LANP(1-30) at a rate of 1 microg/hr for 72 hours. Group 3 (controls, n = 6) was used to measure the baseline creatinine level and had no renal ischemia or surgery. RESULTS: Seventy-two hours post-renal ischemia, the weight loss in the ischemia group was similar to the peptide treated group (7.65 +/- 1.14% and 10.03 +/- 0.9% body weight loss, respectively, p = 0.126). The ischemia group had significantly higher creatinine levels compared to the controls (66.3 +/- 5.3 versus 30.1 +/- 0.9 micromol/L, p = 0.002). The peptide-treated group had higher creatinine (174.1 +/- 77.8 versus 66.3 +/- 5.3 micromol/L, p = 0.035) and LANP(1-30) levels (673.14 +/- 69.64 versus 45.83 +/- 8.45 pg/mL, p = 0.001) than the ischemia group. CONCLUSION: Prolonged use of LANP(1-30) has no renal protective effect.
    [Abstract] [Full Text] [Related] [New Search]